Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vonoprazan Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy Participants

NCT05366738
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vonoprazan
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants

NCT04545944
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vonoprazan, Midazolam
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Sep 2, 2026, 2:22 PM EDT
Active, not recruiting Phase 2 Interventional

A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks

NCT06851559
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Vonoprazan, Placebo
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
41
States / cities
Little Rock, Arkansas • Chula Vista, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease

NCT04799158
View directory record Official record
Conditions
Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn
Interventions
Vonoprazan, Placebo
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
63
States / cities
Anniston, Alabama • Athens, Alabama • Huntsville, Alabama + 55 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 2, 2026, 2:22 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants

NCT04558216
View directory record Official record
Conditions
Healthy Participants
Interventions
Vonoprazan, Rifampin
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 2, 2026, 2:22 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1

NCT07224035
View directory record Official record
Conditions
H Pylori Infection, H Pylori Gastritis, Gastric Cancer
Interventions
PYTEST® 14C-Urea Breath Test, VOQUEZNA® Triple Pak®
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)

NCT05195528
View directory record Official record
Conditions
Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn
Interventions
Vonoprazan, Placebo
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
108
States / cities
Athens, Alabama • Cullman, Alabama • Huntsville, Alabama + 94 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily

NCT06391177
View directory record Official record
Conditions
Erosive Esophagitis, Heartburn, Symptomatic Nonerosive Gasroesophageal Reflux Disease, Helicobacter Pylori Infection
Interventions
Vonoprazan
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 2, 2026, 2:22 PM EDT
Recruiting No phase listed Observational

A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring

NCT06660342
View directory record Official record
Conditions
Erosive Esophagitis, Heartburn, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Helicobacter Pylori Infection
Interventions
Vonoprazan
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
15 Years to 50 Years · Female only
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy Participants

NCT04729101
View directory record Official record
Conditions
Healthy Participants
Interventions
Vonoprazan, Lansoprazole
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease

NCT05343364
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Vonoprazan
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Mobile, Alabama • Little Rock, Arkansas • Anaheim, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants

NCT06831344
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vonoprazan ODT-1 or ODT-2 without Water, Vonoprazan ODT-1 or ODT-2 with Water, Vonoprazan (Reference)
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis

NCT04124926
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Vonoprazan, Lansoprazole
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
109
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 88 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease

NCT06106022
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Vonoprazan
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
Mobile, Alabama • Little Rock, Arkansas • Hollywood, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection

NCT04167670
View directory record Official record
Conditions
Helicobacter Pylori Infection
Interventions
Vonoprazan, Amoxicillin, Clarithromycin, Lansoprazole
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,046 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
106
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 84 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 2, 2026, 2:22 PM EDT